Accumulation of damage is generally considered the cause of aging. Interventions that 14 delay aging mobilize mechanisms that protect and repair cellular components. 15
Introduction

109
Collagen glycation and crosslinking during aging 110
The Maillard reaction is the major non-enzymatic glycation pathway for advanced 111 glycation end-products (AGE) formation [4] . Simplistically described, glucose interacts 112 with lysine and arginine side chains of a protein (e.g., collagen) to form a reversible 113
Schiff base product within hours, which is stabilized to keto amine (Amadori product) 114 within days, and in a series of chemical reactions within weeks to months these are 115 transformed into AGE ( Figure 1B ), such as carboxymethyl-lysine, 3-deoxyglucosone-116 lysine dimer, glyoxal, glucosepane, pentosidine etc [4] . These AGEs are able to 117 crosslink and thus stiffen collagen structures. Glycation and crosslinking of collagens 118 impairs wound healing and is a major problem for diabetes patients with high blood 119 sugar levels [4] . Cells sense this increase in ECM stiffness and respond by expressing 120 ECM-remodeling enzymes to adjust to their preferred matrix stiffness. However, AGEs 121 or crosslinks hinder enzymatic cleavage, potentially leaving these stiffer matrix parts, 122 but cleave the surrounding intact matrix resulting in collateral damage. Ultimately, this 123 leads to stiffer and mechanically weaker matrices during aging. 124
125
Accumulation of protein aggregation in the ECM 126
Aggregation of proteins is a hallmark of many neurodegenerative diseases and is 127 thought to be a crucial factor in their pathogenesis. Post-mortem studies of brains from 128
Parkinson's patients show an intracellular aggregation of -synuclein. Recent 129 evidence suggests that -synuclein aggregates might be actively secreted or released 130 after cell death and taken up by other neurons to spread -synuclein aggregation in a 131 "prion-like fashion" throughout the brain. Injecting mice with antibodies against -132 synuclein helps to clear extracellular -synuclein [14] . Importantly, this kind of "prion-133
like" spreading has been observed in models for Tau pathologies or models for SOD1 134 mutant amyotrophic lateral sclerosis. Interestingly, targeting and clearing extracellular 135 SOD1 by intraventricular infusion of a SOD1-specific antibody delayed the disease-136 onset and increased the lifespan of these SOD1(G93A) transgenic mice [15] . The 137 accumulation of extracellular amyloid peptide (A) has been suggested to be involved 138 in the etiology of neurodegeneration in Alzheimer's disease [16] . How these 139 extracellular aggregates are cleared and how these mechanisms directing this are lost 140 during aging is still unclear. Microglia ("brain macrophages") and autophagy have 141 been implicated in the clearance of extracellular aggregates. However, components 142 of the extracellular matrix itself, such as collagen COL25A1, have emerged from 143 whole-genome sequencing of healthy elderly people to be protective against A 144 pathology [17]. Thus, the ECM might not only be a by-stander that accumulates these 145 aggregate-prone proteins, but might also have a functional role in either safe-storing 146 or clearing these aggregates ( Figure 1C) . Alternatively, these aggregate-prone 147 proteins in the ECM might turnover during the physiological ECM process ( Figure 1C) and proteins that make up a "young or healthy ECM". Recent advances in the field of 187 proteomics and data analysis enable such a quantification of ECM protein 188 compositions. I build on these advances to define a novel concept that will help 189 grasping changes in ECM composition during disease, health, aging, and longevity. Below, I discuss technical challenges and theoretical considerations of the 232 matreotype. As a proof-of-concept, we re-analyzed gene expression and proteomics 233 data to identify a preliminary matreotype during aging and longevity, demonstrating 234 that by combining transcriptomic, proteomic, and genetic approaches, the matreotype 235 of healthy aging can be revealed across species in future approaches. Furthermore, I 236 highlight that identifying and defining matreotypes will be of translational value. 
Technical challenges for quantifying matreotypes 266
There are several technical challenges for quantifying matreotypes that in principle 267 could be overcome. First, quantifying the matreotype through standard proteomics 268 needs to be adopted to enrich for ECM proteins. Since ECM proteins are crosslinked 269 and form high molecular networks, they become insoluble and this insoluble fraction 270 is often discarded. However, there are currently several proteomic protocols that have 271 (Figure 2A, 2B) . 306
Most matrisome genes are expressed during development and growth, but their 307 expression rapidly declines during the reproductive phase (day 1-4 of adulthood; 308 Figure 2C ). There are only three matrisome-associated genes that increase inexpression during aging (cpr-2, chil-14, lec-2; Figure 2C ). CPR-2 is the cathepsin B 310 (CTSB) orthologue and might be involved in ECM degradation. Consistent with 311 observations in mammals, tissue inhibitor of metalloproteases, TIMP-1, expression is 312 also progressively lost during aging ( Figure 2C ). Taken together, we found a general 313 decline of matrisome gene expression during aging for the model organism C. elegans 314 ( Figure 2C ) that is similar to the progressive decline in collagen biosynthesis observed 315 in human skin [10] and across species [8, 9] . A comprehensive assessment of not only 316 the transcriptional matreotype but also of the protein levels in mammalian tissues 317 during aging might be feasible by using an in-situ decellularization protocol coupled 318 with ECM proteomics [36] . This could reveal the longitudinal signature of the 319 matreotype during aging. 320
321
Matreotype during longevity 322
Comparing the gene expression or protein levels at a given chronological age between 323 wild type and long-lived animals revealed several molecular mechanisms at work, 324 which were then experimentally assessed for their functional importance for longevity. 325 
Conclusions 364
Major efforts have revealed how proteins are maintained within cells and cellular 365 compartments and how longevity interventions improve protein homeostasis during 366 aging (Figure 1) . Here, I propose that collagen homeostasis or ECM turnover is a 367 process that works efficiently when the organisms are young to maintain their somatic 368 tissue. Since collagen biosynthesis is costly and energy-intensive, upon reproduction 369 resources might be allocated to produce high quality off-springs. Moreover, ECM 370 turnover might be the repair mechanism to cleave-out, digest, and degrade damaged 371 ECM proteins from the matrix. This requires cellular contact, proper 372 mechanotransduction, and de-novo synthesis of ECM components from cells. 
